CURRICULUM VITAE
Ashley E. Ross MD PhD
Texas Urology Specialists
DEMOGRAPHIC AND PERSONAL INFORMATION
Current Appointments
Urologist, Texas Urology Specialists
PreviousAppointments
Associate Professor, Departments of Urology and Oncology, Johns Hopkins School of Medicine
Director, Johns Hopkins Urology Prostate Cancer Program
Chief Medical Advisor, GenomeDx Biosciences
Education and Training
Undergraduate
8/1994 –5/1997B.S., Biochemistry
University of Maryland, College Park
Doctoral/Graduate
7/1997 –5/2006Doctor of Medicine
Doctor of Philosophy, Mentor Dr. Stephen V. Desiderio
MD / PhD, Medical Scientist Training Program
Johns Hopkins University School of Medicine,
Biochemistry, Cellular and Molecular Biology Program
Baltimore, MD
Post-doctoral
7/2006-6/2007Intern- Johns Hopkins Medical Institution, Department of Surgery
Chair: Julie A. Freischlag
7/2007-6/2009Resident- Johns Hopkins Medical Institution, Department of Urology
Chair: Alan W. Partin MD PhD
7/2009-6/2010Post-Doctoral Research Fellowship, Departments of Urology, Oncology and Pathology, Johns Hopkins Medical Institution
Mentor: Edward M. Schaeffer MD PhD
7/2010-6/2012Chief Resident, Johns Hopkins Medical Institution, Department of
Urology
Chair: Alan W. Partin MD PhD
Professional Experience
7/2012-12/2016Assistant professor Urology, Oncology, Pathology, Johns Hopkins School
of Medicine, Baltimore, MD
12/2015-2/2017Director, Johns Hopkins Urology Prostate Cancer Program
12/2016-4/2017Associate professor Urology and Oncology, Johns Hopkins School of Medicine, Baltimore, MD
3/2017-presentChief Medical Advisor, GenomeDx Biosciences
7/2017-presentUrologist, Texas Urology Specialists
PUBLICATIONS:
Original Research [OR]
1)Tretter T, Ross AE*, Dordai DI, Desiderio S. Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk. J Exp Med. 2003 Dec 15; 198(12): 1863-73.
*Equal contribution first authorship.
2)Ross AE, Vuica M, Desiderio S. Overlapping signals for protein degradation and nuclear localization define a role in intrinsic RAG-2 nuclear uptake in dividing cells. Mol Cell Biol. 2003 Aug;23(15):5308-19.
3)Jiang H, Ross AE, Desiderio S. Cell cycle-dependent accumulation in vivo of transposition-competent complexes between recombination signal ends and full-length RAG proteins. J Biol Chem. 2004 Feb 27;279(9): 8478-86.
4)Jiang H, Chang FC, Ross AE, Lee J, Nakayama K, Nakayama K, Desiderio S. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol Cell 2005 Jun 10;18(6): 699-709.
5)Ross AE, Handa S, Lingeman JE, Matlaga BR. Kidney stones during pregnancy: an investigation into stone composition. Urol Res. 2008 May; 36(2): 99-102.
6)Loeb S, Epstein JI, Ross AE, Shultz L, Humphreys EB, Jarow JP. Benign prostate glands at the bladder neck margin in robotic vs open radical prostatectomy. BJU Int 2010 Mar 25.
7)Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Ketterman A, Feng Z, Carter HB, Walsh PC. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010 Jun 10;28(17):2810-6.
8)Bivalacqua TJ, Ross AE, Strong TD, Gebska MA, Musicki B, Champion HC, Burnett AL. Attenuated RhoA/Rho-Kinase signaling in the penis of transgenic sickle cell mice. Urology. 2010 Aug: 76(2):510.e7-12.
9)Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M. A chemical genetic screen for modulators of asymmetrical 2,2’-dimeric naphthoquinone cytotoxicity in yeast. PLoS ONE 2010, May 26;5(5):e10846.
10)Cilip CM, Ross AE, Jarow J, Fried NM. Application of an optical clearing agent during noninvasive laser coagulation of the canine vas deferens. J Biomed Opt. 2010 Jul-Aug; 15(4):04001.
11)Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M. Dimeric napthoquinones, a novel class of compounds with prostate cancer cytotoxicity. BJU Int. 2010 Dec 22.
12)Ross AE, Marchionni L, Vuica-Ross M, Cheadle C. Fan J, Berman DM, Schaeffer EM. Gene expression pathways of high grade localized prostate cancer. Prostate 2011, Feb 25.
13)Pierorazio PM, Ross AE, Schaeffer EM, Epstein JI, Han M, Walsh PC, Partin AW. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. J Urol 2011. May; 185(5): 1691-7.
14)Ross AE, Marchionni L, Phillips TM, Miller RM, Hurley PJ, Simons BW, Salmasi AH, Schaeffer AJ, Gearhart JP, Schaeffer EM. Molecular effects of genistein on male urethral development. J. Urol 2011. May; 185(5):1894-8.
15)Loeb S, Feng Z, Ross AE, Trock BJ, Humpreys EB, Walsh PC. Can we stop prostate-specific antigen testing 10 years after radical prostatectomy? J Urol 2011. Aug; 186(2): 500-5.
16)Pierorazio PM, Ross AE, Han M, Epstein J, Walsh PC, Partin A, Schaeffer EM. Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJUI 2011, Aug 22.
17)Cilip CM, Pierorazio PM, Ross AE, Allaf ME, Fried NM. High-frequency ultrasound imaging of non-invasive laser coagulation of the canine vas deferens. Lasers Surg Med. 2011 Sep: 43(8): 838-42.
18)Emadi A, Le A, Harwood CJ, Stagliano KW, Kamangar F, Ross AE, Cooper CR, Dang CV, Karp JE, Vuica-Ross M. Metabolic and electrochemical mechanisms of dimeric naphthoquinones in cytotoxicity in breast cancer cells. Bioorg Med Chem. 2011 Dec 1: 19(23): 7057-62.
19)Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM. Effects of treatment with 5-Alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int. 2012 Jan 30.
20)Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int. 2012 Feb28.
21)Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget 2012 Jul 2.
22)Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM. Secreted protein, acidic and rich in cystein-like 1 (SPARCL1) is down regulated in aggressive prostate cancer and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82. Epub 2012 Aug 27.
23)Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, Schaeffer EM. Wnt signaling through beta-catenin is required for prostate lineage specification. Dev Biol. 2012 Aug 30.
24)Sundi D, Ross AE, Humphreys E, Han M. Partin AW, Carter HB, Schaeffer EM. African American men with very low risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy. Is active surveillance still an option? JCO 2013 Aug 20(24)2991-7.
25)Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate 2013 Sept 9.
26)Pierorazio PM, Mullins JK, Ross AE, Hyams ES, Partin AW, Han M, Walsh PC, Schaeffer EM, Pavlovich CP, Allaf ME, Bivalacqua TJ. Trends in immediate peri-operative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience. BJU Int 2013 Jul; 112 (1):45-53.
27)Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. Very high risk localized prostate cancer: definition and outcomes. PCPD 2014. March 17(1): 57-63.
28)Ross AE, Feng FY, Chadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson JS, Triche T, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes J, Schaeffer EM. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. PCPD 2014. March 17(1): 64-9.
29)Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer ME. Pathological examination of radical prostatectomies in men with very-low-risk disease at biopsy reveals distinct zonal distribution of cancer in African American men. J Urol. 2014. 191(1):60-7.
30)Levy DA, Ross AE, Elshafei A, Krishnan N, Hatem A, Jones JS. Definition of biochemical success following whole gland cryoablation. J Urol 2014. May 9.
31)Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE. Outcomes of men with an elevated PSA as their sole pre-operative intermediate or high risk feature. BJU Int 2014. April 15
32)Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ. Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate 2014. May 7.
33)Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA, Ross AE, Schaeffer EM. Establishment of a new prostate cancer muti-disciplinary clinic: format and initial experience. Prostate 2015; 75(2): 191-9.
34)Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, Hurley PJ, Berman DM, Drake CG, Thumbikat P, Schaeffer EM. A human prostatic bacterial isolate alters the prostate microenvironment and accelerates prostate cancer progression. J Pathol. 2015; Feb; 235(3): 478-89.
35)Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, Ross AE, Schaeffer EM. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Uroloy 2014 84(6); 1434-41.
36)Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM. Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology. 2015 85(1): 155-60.
37)Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes.Eur Urol. 2015 May 8. [Epub ahead of print].
38)Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate and High Risk Men.Eur Urol. 2015 Apr 25. [Epub ahead of print].
39)Carvalho FL, Marchionni L, Gupta A, Kummangal BA, Schaeffer EM, Ross AE, Berman DM.HES6 promotes prostate cancer aggressiveness independently of Notch signalling.J Cell Mol Med. 2015 Apr 12. [Epub ahead of print].
40)Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY.High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.Prostate Cancer Prostatic Dis. 2015 May 19. [Epub ahead of print].
41)Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humpreys EB, Faraj S, Bezerra, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue Based Genomics Augment Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. Eur Urol 2015 Jun 6.
42)Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J,Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An S, Schaeffer E. Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Res. 2015 Oct 15; 75(20): 4322-34.
43)Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z,Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM.Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.J Clin Oncol. 2015 Sep 1;33(25):2789-96. Epub 2015 Jul 20.
44)Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer.
Clin Cancer Res. 2015 Oct 7. pii: clincanres.0256.2015.
45)Faisal FA, Sundi D, Tosoian JJ, Choeurng V, Alshalalfa M, Ross AE, Klein E, Den R, Dicker A, Erho N, Davicioni E, Lotan TL, Schaeffer EM.Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.Eur Urol. 2015 Oct 3
46)Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, Ross AE, Jones JS. Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry.J Endourol. 2015 Oct 20.
47)Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY. The landscape of prognostic outlier genes in high-risk prostate cancer. Clin Cancer Res. 2015 Dec 2.
48)Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis E, Eisenberger M, Carducci M, Ross A, Kantoff P, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY. Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med. 2015 Oct 22.
49)Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ. Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS One. 2016 Jan 5;11(1).
50)Schwen ZR, Tosoian JJ, Sokoll LJ, Mangold L, Humphreys E, Schaeffer EM, Partin AW, Ross AE. Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. Urology. 2015 Dec 10.
51)Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis. 2016. May 3.
52)You S, Knudsen BS, Erho N, Alshalalfa M, Takar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res. 2016 Jun 14.
53)Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, Netto G., Partin AW, Trock BJ, Davicioni E, Schaeffer EM. SPINK1 define a molecular subtype of prostate cancer in men with more rapid progression in a at-risk natural history radical prostatectomy cohort. J Urol 2016. May 26.
54)Ghabili K, Tosoian JJ, Schaeffer EM, Pavlovich CP, Golzari SE, Khajir G, Andreas D, Benzon B, Vuica-Ross M, Ross AE. The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies. Urology. 2016 Aug 31.
55)Klein EA, Santiago-Jimenez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE. Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential. J Urol 2016. Aug 25
56)Tosoian JJ, Almutairi F, Morais GL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American men Undergoing Radical Prostatectomy. Eur Urol 2016 Jul 28.
57)Shukla S, Zhang X, Niknafs YS, Xiao L, Mehra R, Cleslik M, Ross A, Schaeffer E, Malik B, Guo S, Freier SM, Bui HH, Siddiqui J, Jing X, Cao X, Dhanasekaran SM, Feng FY, Chinnaiyan AM, Malik R. Identification and Validation of PCAT14 as a Prognostic Biomarker in Prostate Cancer. Neoplasia 2016 Aug: 18(8): 489-99.
58)Benzon, B, Zhao SG, Haffner M, Takhar M, Erho N, Yousef K, Hurley P, Bishop J, Tosoian J, Ghabili K, Alshalafa M, Glavaris S, Simons B, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis E, Schaeffer EM, Drake CG, Feng F, Ross AE. Correlation of B7-H3 with Androgen Receptor, Immune Pathways and Poor Outcomes in Prostate Cancer: An Expression Based Analysis. PCPD 2016 Nov 1. Epub ahead of print.
59)Guedes LB, Tosoian JJ, Hicks J, Ross AE, Lotan TL. PTEN Loss in Gleason Score 3+4=7 Prostate Biopsies is Associated with Non-Organ Confined Disease at Radical Prostatectomy. J Urol 2016 Sep 27. Epub ahead of print.
60)Zhao, SG. Chang L, Spratt DE, Erho, N, Yu M, Ashab HA; Alshalalfa M, Speers C, Tomlins S, Davicioni E, Dicker AP, Carroll PR, Cooperberg M, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng F. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched retrospective analysis. Lancet Oncol 2016 Oct 12. Epub ahead of print.
61)Tosoian JJ, ALam R, Gergis C, Narang A, Radwan N, Robertson S, McNutt T, Ross AE, Song DY, DeWeese TL, Tran PT, Walsh PC. Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease. Prostate Cancer Prostatic Dis. 2017 Jan 3. Epub ahead of print.
62)Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson A, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ,RossAE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubedi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2.
Cancer Res. 2016 Dec 23. pii: canres.2529.2016. doi: 10.1158/0008-5472.CAN-16-2529. [Epub ahead of print]
63)Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME,RossAE, Pienta KJ, Lodge MA, Pomper MG. Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake. J Nucl Med. 2016 Dec 8. pii: jnumed.116.179739. [Epub ahead of print]
64)Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, Paller C, Eisenberger M, Demarzo A, Ross AE, Antonarakis ES. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2016 Dec; 78(6): 1297-1304.
65)Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 May 11. doi: 10.1001/jamaoncol.2017.0751. [Epub ahead of print]PMID:28494073
66)Malek R, Gajula RP, Williams RD, Nghiem B, Simons BW, Nugent K, Wang H, Taparra K, Lemtiri-Chlieh G, Yoon AR, True L, An SS, DeWeese TL, Ross AE, Schaeffer EM, Pienta KJ, Hurley PJ, Morrissey C, Tran PT. TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancermetastasis.Cancer Res. 2017 May 8. pii: canres.2797.2016. doi: 10.1158/0008-5472.CAN-16-2797. [Epub ahead of print]PMID:28484075
67)Tosoian JT, Chappidi MR, Bishoff JT, Freedland SJ, Reid J, Brawer M, Stone S, Schlomm T, Ross AE. Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance. BJU Int. 2017 May 8. doi: 10.1111/bju.13911. [Epub ahead of print] PMID:28481440
68)Guedes L, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto G, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL. Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer. Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017. doi: 10.1158/1078-0432.CCR-17-0257. [Epub ahead of print]PMID:28446506
69)Nyame YA, Elshafei A, Greene DJ, Arora HC, Given RW, Tay KJ, Polascik TJ, Ross AE, Mouraviev VB, Lugnani F, Jones JS. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.J Endourol. 2017 May;31(5):497-501. doi: 10.1089/end.2016.0715.PMID:28437170
70)Tosoian JJ, Patel HD, Mamawala M, Landis P, Wolf S, Elliott DJ, Epstein JI, Carter HB, Ross AE, Sokoll LJ, Pavlovich CP. Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. Prostate Cancer Prostatic Dis. 2017 Apr 18. doi: 10.1038/pcan.2017.16. [Epub ahead of print]PMID:28417979
71)Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264-6. doi: 10.1016/j.eururo.2017.03.036. [Epub ahead of print]PMID:28400167